Pharma BD Deal Intelligence
A $2.4B buyout of the 43% of Foundation Medicine it didn't already own gave Roche full control of the FoundationOne CDx genomic profiling platform, pairing companion diagnostics directly with its oncology pipeline. The move deepened Roche's precision-oncology bet, anchoring drug development around a proprietary 300,000+ sample genomic database.
Roche acquired the remaining shares of Foundation Medicine for $137 per share to accelerate broad availability of comprehensive genomic profiling in oncology…
Tender offer expired 12:00 midnight ET end of July 30, 2018; Roche accepted all validly tendered shares at $137.00/share. Following the second-step merger, FMI…
Roche's subsidiary accepted for payment all shares validly tendered and not validly withdrawn in its tender offer for Foundation Medicine at $137.00 per share;…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche acquired the remaining ~43% of Foundation Medicine it did not already own for approximately $2.4 billion ($137 per share), implying a total equity value of ~$5.3 billion. The deal gave Roche full control of FMI's comprehensive genomic profiling platform, FoundationOne CDx, to pair diagnostics with its oncology therapeutics.
1.9M US cases/yr · $8.0B Global cancer diagnostics/CGP
Comprehensive genomic profiling (CGP) tests analyze hundreds of cancer-related genes simultaneously. As targeted therapies and tumor-agnostic approvals expand, CGP has become essential for treatment selection in advanced solid tumors.
FoundationOne CDx (Roche), Tempus xT, Caris Molecular Intelligence, Guardant360 CDx (liquid biopsy). Increasing payer coverage and NCCN recommendations driving adoption.
190K US cases/yr · $60.0B Global hematologic oncology
Hematologic malignancies include leukemias, lymphomas, and myelomas. CAR-T, bispecifics, BTK inhibitors, and venetoclax have transformed treatment across subtypes.
CAR-T therapy, bispecific antibodies, BTK inhibitors, BCL-2 inhibitors, anti-CD38/CD20 antibodies. Key players: BMS, J&J, Roche, AbbVie, Gilead/Kite, Pfizer.
Roche to acquire remaining 43% at $137/share, implying ~$5.3B total value. Part of Roche Holding AG's $5.3B deal to acquire Foundation Medicine, Inc..
Roche Holding AG completed its acquisition of Foundation Medicine, Inc. for $5.3B. Roche acquired the remaining ~43% of Foundation Medicine it did not already own for approximately $2.4 billion ($137 per share), implying a total equity value of ~$5.3 billion.
Tender offer (commenced 2018-07-02) expired 2018-07-30; on 2018-07-31 Roche accepted for payment ~12,535,376 shares (~77.28% of non-Roche shares). Second-step merger followed promptly, making Foundation Medicine a wholly owned Roche subsidiary and delisting it from NASDAQ.
Medicare NCD enabled NGS reimbursement across all solid tumors. Regulatory step in Roche Holding AG's acquisition process for Foundation Medicine, Inc..
FoundationOne CDx established as leading CGP test with companion Dx deals across industry.
See timeline for full assessment. Assessment of Roche Holding AG's $5.3B acquisition of Foundation Medicine, Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Foundation Medicine, Inc. (this deal) | 2018 | $5.3B | 85 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2018 deals · Roche Holding AG deals · Oncology deals